Immunome Inc. — Form 10-Q
Filed August 11, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Immunome Inc. established a 2024 Inducement Plan effective October 3, 2024, amended May 8, 2025 and May 12, 2026, authorizing up to 5,000,000 shares of common stock for equity awards to newly hired employees. The plan permits nonstatutory stock options, SARs, restricted stock, RSUs, and performance awards, with grants approved by independent directors or compensation committee. All awards are inducement grants under Nasdaq Rule 5635(c)(4), requiring no stockholder approval.
Why this rating
Standard equity plan adoption for talent acquisition. 5M shares (~0.69% of $728.5M market cap on diluted basis) is routine for company of this size; immaterial relative to market value.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.